You have read all your free articles, to continue reading subscribe to read the rest of this content.
Cantargia announces that the United States Patent and Trademark Office has granted the company's patent application directed to the product candidate CAN04. The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the iAlready a subscriber Login You have…
Ultimovacs has announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma. UV1, as add-on therapy to checkpoint inhibitors ipilimumab and nivolumab, is currently beiAlready a subscriber Login You have…
Chinese investment firm Ivy Capital is investing almost three million USD into Umeå-based biotechnology firm Betagenon. Betagenon has identified an enzyme activator that is intended as a drug candidate for multiple lifestyle and age disorders such as diabetes and heart failure. Ivy Capital is noAlready a subscriber Login You have…
Calliditas Therapeutics has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing Calliditas’ common shares, in the United States and a concurrent private pAlready a subscriber Login You have read all…
